

# Nathalie A Johnson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3933547/publications.pdf>

Version: 2024-02-01

62  
papers

5,066  
citations

236925

25  
h-index

168389

53  
g-index

62  
all docs

62  
docs citations

62  
times ranked

6018  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 2125-2132.	1.6	830
2	Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2012, 30, 3452-3459.	1.6	824
3	MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. <i>Blood</i> , 2009, 114, 3533-3537.	1.4	566
4	Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. <i>Blood</i> , 2009, 114, 2273-2279.	1.4	523
5	Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. <i>Blood</i> , 2019, 134, 1144-1153.	1.4	255
6	Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. <i>Clinical Cancer Research</i> , 2016, 22, 2290-2300.	7.0	186
7	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. <i>PLoS Medicine</i> , 2016, 13, e1002197.	8.4	185
8	Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. <i>Blood</i> , 2016, 127, 2182-2188.	1.4	145
9	Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2021, 22, 512-524.	10.7	144
10	Approach to the diagnosis and treatment of high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements. <i>Blood</i> , 2017, 129, 280-288.	1.4	125
11	Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. <i>Blood</i> , 2009, 113, 137-148.	1.4	122
12	Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. <i>Blood</i> , 2016, 128, 185-194.	1.4	122
13	Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 3081-3089.	1.6	120
14	The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. <i>Blood</i> , 2008, 112, 3126-3129.	1.4	112
15	A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2021, 137, 600-609.	1.4	79
16	Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. <i>Blood</i> , 2009, 113, 2298-2301.	1.4	75
17	Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR. <i>Scientific Reports</i> , 2020, 10, 12564.	3.3	69
18	Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP. <i>Haematologica</i> , 2010, 95, 96-101.	3.5	63

#	ARTICLE	IF	CITATIONS
19	CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. <i>Haematologica</i> , 2009, 94, 423-427.	3.5	53
20	Prognostic significance of secondary cytogenetic alterations in follicular lymphomas. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 1038-1048.	2.8	50
21	Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma. <i>Clinical Chemistry</i> , 2016, 62, 1238-1247.	3.2	45
22	Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing. <i>Blood</i> , 2020, 136, 572-584.	1.4	44
23	Pembrolizumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Primary End Point Analysis of the Phase 2 Keynote-087 Study. <i>Blood</i> , 2016, 128, 1107-1107.	1.4	36
24	Colorimetric In Situ Hybridization Identifies MYC Gene Signal Clusters Correlating With Increased Copy Number, mRNA, and Protein in Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Pathology</i> , 2013, 139, 242-254.	0.7	29
25	Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study. <i>Blood</i> , 2018, 132, 782-782.	1.4	27
26	KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8005-8005.	1.6	24
27	Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baits. <i>Scientific Reports</i> , 2017, 7, 10574.	3.3	20
28	Three-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 240-240.	1.4	20
29	Five-Year Follow-up of Keynote-087: Pembrolizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL). <i>Blood</i> , 2021, 138, 1366-1366.	1.4	20
30	Cell of origin in diffuse large B-cell lymphoma in systemic lupus erythematosus: molecular and clinical factors associated with survival. <i>Lupus Science and Medicine</i> , 2019, 6, e000324.	2.7	16
31	Disruption of direct 3D telomere-TRF2 interaction through two molecularly disparate mechanisms is a hallmark of primary Hodgkin and Reed-Sternberg cells. <i>Laboratory Investigation</i> , 2017, 97, 772-781.	3.7	14
32	Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 950-954.	1.3	13
33	Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 2900-2900.	1.4	13
34	Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7555-7555.	1.6	11
35	B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. <i>Vaccine</i> , 2022, 40, 1203-1207.	3.8	11
36	Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. <i>Blood Advances</i> , 2022, 6, 590-599.	5.2	10

#	ARTICLE	IF	CITATIONS
37	Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling. <i>Cancers</i> , 2021, 13, 1002.	3.7	9
38	Favezelimab (anti- $\text{LAG-3}$ ) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti- $\text{PD-1}$ treatment: An open-label phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7545-7545.	1.6	7
39	The genomic landscape of two Burkitt lymphoma cases and derived cell lines: comparison between primary and relapse samples. <i>Leukemia and Lymphoma</i> , 2018, 59, 2159-2174.	1.3	6
40	A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-8.	1.3	5
41	Do Mountain Bikers Know When They Have Had a Concussion and, Do They Know to Stop Riding?. <i>Clinical Journal of Sport Medicine</i> , 2019, Publish Ahead of Print, e414-e419.	1.8	5
42	Targeted Sequencing Reveals Novel Gene Mutations Associated with Transformation and Early Progression in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 2919-2919.	1.4	5
43	Methods for Sample Acquisition and Processing of Serial Blood and Tumor Biopsies for Multicenter Diffuse Large B-cell Lymphoma Clinical Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 2688-2693.	2.5	4
44	Common clonal origin of chronic myelomonocytic leukemia and B-cell acute lymphoblastic leukemia in a patient with a germline CHEK2 variant. <i>Journal of Physical Education and Sports Management</i> , 2021, 7, a006090.	1.2	4
45	Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Preliminary Results from the Phase 2 CheckMate 436 Trial. <i>Blood</i> , 2018, 132, 1691-1691.	1.4	4
46	Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy. <i>Blood</i> , 2020, 136, 12-12.	1.4	4
47	Fas Mutations in Non-Hodgkin's Lymphoma (NHL): Implications for Disease Progression and Therapeutic Resistance. <i>Blood</i> , 2019, 134, 1520-1520.	1.4	2
48	Phase I/II study of avadomide (CC-122) in combination with R-CHOP for newly diagnosed DLBCL.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3501-3501.	1.6	2
49	Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study. <i>Blood</i> , 2020, 136, 19-20.	1.4	2
50	Favezelimab (anti- $\text{LAG-3}$ ) plus pembrolizumab in patients with anti- $\text{PD-1}$ -naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7516-7516.	1.6	2
51	FAS Mutations Accelerate Lymphoma Growth and Induce Therapeutic Resistance. <i>Blood</i> , 2014, 124, 3018-3018.	1.4	1
52	Disruption of Direct 3-Dimensional (3D) Telomere-TRF2 (Telomere Related Factor 2) Interaction Is a Hallmark of Primary Hodgkin (H) and Reed-Sternberg (RS) Cells. <i>Blood</i> , 2015, 126, 177-177.	1.4	1
53	The Copy Number Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 8-9.	1.4	1
54	Three-Dimensional Telomere Analysis Using Teloview <sup>®</sup> Technology Predicts the Response of Classic Hodgkin's Lymphoma Patients to First Line Therapy at Point of Diagnosis. <i>Blood</i> , 2020, 136, 36-37.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Targeting EVI1-Overexpressing AML with Darinaparsin. Blood, 2011, 118, 4269-4269.	1.4	0
56	Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis. Blood, 2011, 118, 556-556.	1.4	0
57	Large-Scale High Resolution Integration of Copy Number and Gene Expression in DLBCL Reveals Focal and Frequent Deletions in Chromatin Modifying Genes with Outcome Correlation. Blood, 2012, 120, 295-295.	1.4	0
58	A Randomized, Phase II Study with Biomarker Analysis of Panobinostat with or without Rituximab in Relapsed Diffuse Large B Cell Lymphoma. Blood, 2015, 126, 2719-2719.	1.4	0
59	Apoptotic Blocks in Primary Non-Hodgkin B-Cell Lymphomas Identified By BH3 Profiling. Blood, 2018, 132, 4126-4126.	1.4	0
60	Tumor Lysis Syndrome: Incidence, Mitigation and Management in Patients with Chronic Lymphocytic Leukemia Initiating Venetoclax in Routine Clinical Practice (DEVOTE) across Canada. Blood, 2021, 138, 3744-3744.	1.4	0
61	Single-Cell Transcriptomic Profiling of De Novo and Relapsed Acute Myeloid Leukemia Identifies a Leukemic Stemness Program Shared across Diverse Phenotypes. Blood, 2020, 136, 1-1.	1.4	0
62	Immune profiling of a patient with relapsed HIV-Related and EBV-positive diffuse large B-Cell lymphoma treated with pembrolizumab. Leukemia and Lymphoma, 2021, , 1-5.	1.3	0